Overview
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Ertugliflozin is the fourth sodium glucose co-transporter-2 inhibitor to be licensed in the UK. It is indicated as an adjunct to diet and exercise control to improve glycaemic control in adults with type 2 diabetes.
This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.